ERBB2 and breast carcinoma: Notably, IL-6 can induce resistance development in breast cancer cells against cytotoxic drugs intended for ERα+ breast cancer (like paclitaxel and doxorubicin) and anti-HER2+ breast cancer treatment, like Herceptin [51].